S15-441 CRISPR/Cas9-mediated Genome Editing to Treat EGFR-mutant Lung Cancer Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC. Huibin Tang Joseph Shrager